微创肾单位保留术对肾癌患者免疫相关指标的影响  

Effect of minimally nephron-sparing surgery on levels of immune function of patients with renal carcinoma

作　　者：薛智淞 向宸辉[2] 刘小勇[2] 姚俊成 向颖[1] 杨祺 XUE Zhisong;XIANG Chenhui;LIU Xiaoyong;YAO Juncheng;XIANG Ying;YANG Qi(Department of Urological Andrology, East Hospital, Sichuan Provincial People's Hospital, Sichuan Academy of Medicine,Chengdu 610000, China;Department of Urology, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China)

机构地区：[1]四川省医学科学院·四川省人民医院东院泌尿男科,四川成都610000 [2]成都医学院第一附属医院泌尿外科,四川成都610500

出　　处：《西部医学》2019年第8期1206-1209,共4页Medical Journal of West China

基　　金：四川省卫计委科研课题(90114)

摘　　要：目的探讨微创肾单位保留术(MNSS)对肾癌患者CD105、CD146及CK19的影响。方法选取2013年1月~2014年11月四川省人民医院东院治疗的肾癌患者96例为研究对象,按照随机数字表法分为MNSS组(n=48)与RN组(n=48)。RN组行根治性肾切除术(RN),MNSS组行MNSS治疗。观察两组患者手术相关指标,术前、术后1、90d及1年血清肌酐、CD105、CD146及CK19水平和术后3年无瘤生存情况。结果MNSS组术中出血量、手术时间均大于RN组,而术后引流时间、住院时间均小于RN组(均P<0.05)。MNSS组术后1、90d及1年血清肌酐水平低于RN组(均P<0.05)。术后90d,两组血清CD105、CD146及CK19均较术前减小(均P<0.05)。术后90d,两组血清CD105、CD146及CK19比较,差异无统计学意义(P>0.05)。术后3年,MNSS组无瘤生存率(83.33%)与RN组(87.50%)比较,差异无统计学意义(P>0.05)。结论MNSS治疗肾癌可尽量保留肾功能,降低血清CD105、CD146及CK19水平,疗效显著。Objective To study the effect of Laparoscope nephron-sparing surgery (MNSS) on CD105, CD146 and CK19 of patients with renal carcinoma. Methods96 patients with renal carcinoma treated in East Hospital, Sichuan Provincial People's Hospital, Sichuan Academy of Med from January 2013 to November 2014 were selected, and divided into MNSS group ( n =48) and RN group ( n =48) according to the random number table method. Patients in RN group were performed radical nephrectomy (RN), and those in SS group were performed MNSS. The operation related indicators, the levels of serum creatinine before operation and 1d, 90d and 1 year after operation, serum levels of CD105, CD146 and CK19 and the tumor-free survival situation 3 years after operation of the two groups were observed. ConclusionThe intraoperative blood loss and operation time in MNSS group were greater than those in RN group, and the postoperative drainage time and postoperative hospital stay were less than those in RN group( P < 0.05 ). The levels of serum creatinine 1d, 90d and 1 year after operation in MNSS group were lower than those in RN group ( P < 0.05). At 90d after operation, the serum levels of CD105, CD146 and CK19 in the two groups were lower than those before operation ( P < 0.05), and the difference in the serum levels of CD105, CD146 and CK19 between the two groups was not statistically significant ( P > 0.05). At 3 years after operation, there was no significant difference in disease free survival rate between MNSS group (83.33%) and RN group (87.50%)( P > 0.05);ConclusionMNSS can preserve renal function and reduce serum levels of CD105, CD146 and CK19 in treating patients with renal carcinoma.

关 键 词：微创肾单位保留术 肾癌 CD105 CD146 CK19 

分 类 号：R692[医药卫生—泌尿科学]